Montag & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.4M Buy
28,752
+543
+2% +$550K 1.23% 14
2025
Q4
$30.3M Buy
28,209
+5,906
+26% +$5.65M 1.38% 10
2025
Q3
$17M Sell
22,303
-335
-1% -$249K 0.78% 30
2025
Q2
$17.6M Sell
22,638
-284
-1% -$221K 0.86% 26
2025
Q1
$18.9M Sell
22,922
-573
-2% -$477K 0.95% 24
2024
Q4
$18.1M Sell
23,495
-5,119
-18% -$4.24M 0.86% 27
2024
Q3
$25.4M Buy
28,614
+1,263
+5% +$1.14M 1.2% 13
2024
Q2
$24.8M Sell
27,351
-415
-1% -$332K 1.25% 13
2024
Q1
$21.6M Sell
27,766
-1,245
-4% -$886K 1.08% 18
2023
Q4
$16.9M Sell
29,011
-847
-3% -$494K 0.94% 25
2023
Q3
$16M Sell
29,858
-586
-2% -$302K 1.01% 20
2023
Q2
$14.3M Sell
30,444
-3,887
-11% -$1.63M 0.88% 25
2023
Q1
$11.8M Sell
34,331
-4,138
-11% -$1.4M 0.77% 27
2022
Q4
$14.1M Sell
38,469
-1,497
-4% -$531K 0.94% 21
2022
Q3
$12.9M Sell
39,966
-850
-2% -$269K 0.89% 20
2022
Q2
$13.2M Sell
40,816
-463
-1% -$139K 0.86% 25
2022
Q1
$11.8M Sell
41,279
-202
-0.5% -$52K 0.63% 36
2021
Q4
$11.5M Buy
41,481
+14,320
+53% +$3.63M 0.57% 43
2021
Q3
$6.28M Sell
27,161
-404
-1% -$99.7K 0.34% 81
2021
Q2
$6.33M Sell
27,565
-1,425
-5% -$286K 0.34% 84
2021
Q1
$5.42M Buy
28,990
+33
+0.1% +$6.46K 0.31% 91
2020
Q4
$4.89M Sell
28,957
-11
-0% -$1.64K 0.3% 89
2020
Q3
$4.29M Sell
28,968
-200
-0.7% -$31K 0.35% 79
2020
Q2
$4.79M Sell
29,168
-100
-0.3% -$15.3K 0.42% 68
2020
Q1
$4.06M Sell
29,268
-5,303
-15% -$729K 0.41% 70
2019
Q4
$4.54M Sell
34,571
-1,500
-4% -$174K 0.36% 73
2019
Q3
$4.03M Sell
36,071
-1,482
-4% -$165K 0.35% 74
2019
Q2
$4.16M Sell
37,553
-24,355
-39% -$2.87M 0.37% 68
2019
Q1
$8.03M Sell
61,908
-30,010
-33% -$3.65M 0.74% 35
2018
Q4
$10.6M Sell
91,918
-1,778
-2% -$199K 1.14% 19
2018
Q3
$10.1M Buy
93,696
+55,180
+143% +$5.52M 0.88% 27
2018
Q2
$3.29M Sell
38,516
-275
-0.7% -$22.6K 0.34% 83
2018
Q1
$3M Sell
38,791
-1,726
-4% -$139K 0.31% 91
2017
Q4
$3.42M Sell
40,517
-1,649
-4% -$140K 0.33% 91
2017
Q3
$3.61M Sell
42,166
-1,534
-4% -$126K 0.39% 75
2017
Q2
$3.6M Sell
43,700
-6,485
-13% -$529K 0.4% 67
2017
Q1
$4.22M Sell
50,185
-1,275
-2% -$102K 0.47% 61
2016
Q4
$3.79M Buy
51,460
+250
+0.5% +$18.6K 0.45% 70
2016
Q3
$4.11M Buy
51,210
+450
+0.9% +$36K 0.52% 63
2016
Q2
$4M Sell
50,760
-300
-0.6% -$22.6K 0.53% 64
2016
Q1
$3.68M Buy
51,060
+1,525
+3% +$115K 0.52% 62
2015
Q4
$4.17M Buy
49,535
+1,335
+3% +$111K 0.61% 52
2015
Q3
$4.03M Sell
48,200
-1,000
-2% -$84.4K 0.63% 53
2015
Q2
$4.11M Sell
49,200
-12,346
-20% -$941K 0.6% 56
2015
Q1
$4.47M Buy
61,546
+900
+1% +$64.1K 0.65% 50
2014
Q4
$4.18M Buy
60,646
+3,061
+5% +$207K 0.63% 53
2014
Q3
$3.73M Buy
57,585
+1,715
+3% +$109K 0.62% 54
2014
Q2
$3.47M Buy
55,870
+50,940
+1,033% +$3.04M 0.57% 59
2014
Q1
$290K Buy
+4,930
New +$275K 0.05% 196
2013
Q4
Sell
-27,050
Closed -$1.36M 232
2013
Q3
$1.36M Hold
27,050
0.25% 108
2013
Q2
$1.33M Buy
+27,050
New +$1.47M 0.27% 104

Other funds holding LLY

Montag & Associates's LLY Position: Q1 2026 in Review

Montag & Associates increased its Eli Lilly (LLY) stake by 1.9% in Q1 2026, buying an estimated $550K and bringing the position to 28,752 shares worth $26.4M. The position accounts for 1.23% of the portfolio, ranked #14.

Montag & Associates first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. The position peaked at $30.3M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Montag & Associates held 28,752 shares of Eli Lilly worth $26.4M as of Q1 2026.
  • Montag & Associates bought 543 Eli Lilly shares in Q1 2026, an estimated $550K.
  • Eli Lilly made up 1.23% of Montag & Associates's portfolio in Q1 2026, its #14 holding.
  • Montag & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
  • Montag & Associates's Eli Lilly position peaked at $30.3M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.